ArticleBMC health services research2019

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.

Kerry Mansell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.